Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 3 3Phase 1/2 3Phase 1 2Phase 4 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Burkitt Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1

Interventions

pembrolizumab 223Carboplatin 218Cisplatin 205Paclitaxel 182Gemcitabine 149Docetaxel 127Capecitabine 114Dexamethasone 102Pemetrexed 101Cyclophosphamide 101Specimen Handling 99Magnetic Resonance Spectroscopy 97Oxaliplatin 96Radiotherapy 95Doxorubicin 91Fluorouracil 87Bevacizumab 83Nivolumab 74Leucovorin 72Rituximab 70Vincristine 67durvalumab 66Lenalidomide 63Etoposide 62atezolizumab 61Radiation 61Irinotecan 60130-nm albumin-bound paclitaxel 57Prednisone 56Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Inotuzumab Ozogamicin × 1 year × Clear all
NCT03150693 2026-06-02

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Alliance for Clinical Trials in Oncology

Phase 3 Recruiting
310 enrolled
Lymphoid

Burkitt Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

NCT07476729 2026-03-17

International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

Charite University, Berlin, Germany

Phase 3 Not yet recruiting
750 enrolled
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡